ARS Pharmaceuticals Announced The Publication Of Its Full Pharmacokinetic And Pharmacodynamic Results From One Of Its Four Primary Registration Studies Of Neffy In The Journal Of Allergy And Clinical Immunology
Portfolio Pulse from Benzinga Newsdesk
ARS Pharmaceuticals has published the full pharmacokinetic and pharmacodynamic results from one of its four primary registration studies of Neffy in the Journal of Allergy and Clinical Immunology. The results showed that Neffy resulted in robust responses on pharmacodynamic surrogates of efficacy observed even at 1 minute after dosing, and which were comparable to, or greater in magnitude than, EpiPen.
October 03, 2023 | 1:06 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
ARS Pharmaceuticals' study results for Neffy could potentially impact the stock of SPRY positively, as the results were favorable and comparable or greater than a well-known product, EpiPen.
The positive results from the study of Neffy, a product of ARS Pharmaceuticals, could potentially increase investor confidence in the company, leading to a rise in the stock price of SPRY. The fact that Neffy's efficacy was comparable or greater than EpiPen, a well-known product, adds to this potential positive impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100